TITLE

No end in sight for adult hepatitis B vaccine shortage

AUTHOR(S)
Collier, Roger
PUB. DATE
September 2010
SOURCE
CMAJ: Canadian Medical Association Journal;9/7/2010, Vol. 182 Issue 12, pE580
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on the shortage of adult hepatitis B vaccine supply in Canada, which started in January 2009 when Merck & Co. Inc. announced supply disruptions. It states that Merck & Co. has addressed the issue through investments in manufacturing capabilities and establishment of new vaccine-production facilities. Moreover, Canada has purchased more than 350,000 doses of vaccine from GlaxoSmithKline (GSK), in which GSK helps provide the needed vaccine for school-based hepatitis B programs.
ACCESSION #
54111078

 

Related Articles

  • FDA approval of change in pediatric formulation for Recombivax HB Registered Trademark.  // MMWR: Morbidity & Mortality Weekly Report;1/22/1999, Vol. 48 Issue 2, p34 

    Reports on the discontinued production and distribution of the recommended dosage of Recombivax HB, a pediatric hepatitis B vaccine, effective August 27, 1998. Company responsible for the discontinued production of the drug; Dosage of the drug previously used for the vaccination of adolescents...

  • Dynavax's Heplixav Hits Endpoint in HBV Trial.  // Bioworld Week;8/11/2008, Vol. 16 Issue 32, p4 

    The article reports on the announcement made by Dynavax Technologies Corp. together with partner Merck & Co. Inc. that the Phase III trial of hepatitis B vaccine Heplisav has met its endpoint of inducing a noninferior antibody response compared to Engerix-B, the hepatitis B vaccine marketed by...

  • SECTION 9 IMMUNE SYSTEM.  // MPR - Residents' Edition;Spring/Summer2011, Vol. 20 Issue 1, p110 

    The article offers brief information on various drugs for the immune system including varicella virus vaccine Varivax from Merck & Co. Inc, Twinrix for hepatitis A and hepatitis B immunization from GlaxoSmithKline, and meningitis vaccine Menactra from Sanofi Pasteur Inc.

  • French Decision Helps Parents in Vaccine Lawsuits.  // Natural Life;Jul/Aug2001, Issue 80, p21 

    Focuses on the court decision on the hepatitis B vaccine manufactured by Glaxo SmithKline thought to cause multiple sclerosis of two women. Effects of a triple vaccine on autistic children; Complications of the vaccine; Relationship between vaccination and disease.

  • Efforts to improve vaccine stabilization heat up. Wadman, Meredith // Nature Medicine;Nov2009, Vol. 15 Issue 11, p1232 

    The article focuses on the efforts of scientists and pharmaceutical companies to create vaccine temperature stability. It notes that researchers led by Dexiang Chen at Program for Appropriate Technology in Health (PATH) added to the hepatitis B vaccine a compound called propylene glycol in order...

  • Pharmacovigilance & Regulatory News.  // Reactions Weekly;4/5/2008, Issue 1196, p2 

    This section offers news briefs on the pharmaceutical industry. Consumers are advised by Health Canada not to use products containing ephedrine or the botanical ephedra either alone or in combination with caffeine or other stimulants. An early communication has been issued by the U.S. Food and...

  • Merck Paying $31M Up Front In Dynavax HBV Vaccine Deal. Osborne, Randall // BioWorld Today;11/2/2007, Vol. 18 Issue 214, p1 

    The article reports on the payment of $31.5 million by Merck & Co. Inc. to Dynavax Technologies Corp. to develop the Phase III hepatitis B virus vaccine Heplisav. This forms part of the $105 million in potential milestone payments plus royalties as the two firms look forward to filing for...

  • Merck Dumps Heplisav in Wake of Regulatory Issues. Morrison, Trista // BioWorld Today;12/22/2008, Vol. 19 Issue 247, p1 

    This article reports on the decision by Merck & Co. Inc. to bail out its partnership on hepatitis B vaccine Heplisav in 2008. Merck made the decision after a case of vasculitis derailed development of the vaccine by Dynavax Technologies Corp. Dynavax remains confident in Heplisav and it may seek...

  • Sanofi-Aventis/Merck: Hexavac's hex.  // PharmaWatch: Monthly Review;Nov2005, Vol. 4 Issue 11, p33 

    The article reports that Sanofi-Aventis SA and Merck & Co. Inc. have suspended their pediatric vaccine 'Hexavac' on the recommendation of European regulators. It is reported that the vaccine is not adequately protecting the children against hepatitis B. The suspension is reported temporary and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics